RFA-NS-23-014: Extracellular RNA Sequencing Research Resource for the Accelerating Medicines Partnership Parkinsons Disease (AMPPD) (R24 - Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on September 19, 2022.
From the official notice on Grants.gov, last changed July 8, 2022. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR24
- Clinical trialsNot allowed
- Funded byNINDS
- Median yearly award$2.3 million
- Typical project length3 years
- R24, Resource-Related Research Project. Resources that serve a research field, such as databases, tools or shared methods. Other open R24 notices.
Projects funded under RFA-NS-23-014 were run by National Institute of Neurological Disorders and Stroke (NINDS, 1 project). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-NS-23-014 in the NIH Guide.
Key dates
| Posted | July 8, 2022 |
|---|---|
| Deadline | September 19, 2022 |
| Archived by Grants.gov | October 25, 2022 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Is this a realistic fit?
- Most of the program's money (70% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
This funding opportunity announcement (FOA) seeks applicants experienced in the isolation and sequencing of RNA from brain-derived extracellular vesicles to develop a research resource for the Accelerating Medicines Partnership in Parkinson's Disease (AMP PD). Approximately 2400 blood samples will be provided for this project from existing Parkinson's disease and normal control cohorts that already have longitudinal clinical and sequencing data that is publicly available to interested researchers. It is intended that this resource will become a part of the AMP PD Knowledge Platform, where it will be broadly shared with the research community.
Funded under RFA-NS-23-014 so far
NIH funded 1 project under RFA-NS-23-014 in fiscal 2023, at 1 institution. The median yearly award was $2.3 million.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| A Large-scale Extracellular Vesicle RNA-seq Resource for Parkinsons Disease | Translational Genomics Research Inst | 2023 | $2.3 million |
Who has won Drug Use and Addiction Research Programs grants before
From fiscal 2021 to 2025, Drug Use and Addiction Research Programs (93.279) awarded $7.3 billion across 5,071 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Yale Univ | Connecticut | 150 | $305 million |
| The Johns Hopkins University | Maryland | 156 | $262 million |
| University of California, San Diego | California | 120 | $242 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 100 | $182 million |
| New York University | New York | 62 | $173 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-NS-23-014 still open?
No. It closed on September 19, 2022.
Who can apply for Extracellular RNA Sequencing Research Resource for the Accelerating Medicines Partnership Parkinsons Disease (AMPPD) (R24 - Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Extracellular RNA Sequencing Research Resource for the Accelerating Medicines Partnership Parkinsons Disease (AMPPD) (R24 - Clinical Trial Not Allowed)?
Closed September 19, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under RFA-NS-23-014?
NIH RePORTER lists 1 project funded under RFA-NS-23-014 in fiscal 2023, at 1 institution.
Who has won Drug Use and Addiction Research Programs grants before?
The largest recipients over five fiscal years were Yale Univ, The Johns Hopkins University, University of California, San Diego. The program made 5,071 awards worth $7.3 billion in that time.
Similar open grants
- Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)
- National Centers for Cryo-electron Tomography (cryoET) (R24 -Clinical Trial Not Allowed)
- Tribal Institutional Review Board Establishment and Enhancement (TIRBEE) (R24 - Clinical Trial Not Allowed)
- NIGMS National and Regional Resources (R24 - Clinical Trial Not Allowed)
- Somatic Mosaicism across Human Tissues (SMaHT) Program: Tissue Procurement Center (R24 Clinical Trial Not Allowed)
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)